References
1 CDRI communication No. 6299.
2a
Jaurish E.
Quintana D.
Balders M.
Garcia-Perez E.
Tetrahedron:
Asymmetry
1996,
7:
2233 ;
and references cited therein
2b
Chu KS.
Negrette GR.
Konopleski JP.
Lankner FJ.
Woo NT.
Olmstead MM.
J.
Am. Chem. Soc.
1992,
114:
1800
2c
Lankner FJ.
Chu KS.
Negrette GR.
Synlett
2002,
643
2d
Lankner FJ.
Chu KS.
Negrette GR.
Konopleski JP.
Org.
Synth.
1996,
73:
201
3a
The Chemistry of β-lactams
Page MI.
Chapman and
Hall;
London:
1992.
3b
Organic Chemistry
of β-Lactams
George GI.
VCH
Publishers;
New York:
1992.
4
Sapotola AF. In
Chemistry and Biochemistry of Amino Acids,
Peptides and Proteins
Barrett GC.
Chapman and
Hall;
London:
1985.
5a
Venkatachalam TK.
Tuel LA.
Sudebeck EA.
Uckun FM.
Bioorg. Med. Chem. Lett.
1998,
8:
1461
5b
Sudebeck EA.
Mao C.
Vig R.
Venkatachalam TK.
Tuel LA.
Antimicrob. Agents Chemother.
1998,
42:
3225
6
Burchenal JHK.
Ciovacco K.
Kalhar K.
Toole TO.
Kiefner R.
Dowing MD.
Chu CK.
Watanabe KA.
Wempen I.
Fox JJ.
Cancer
Research
1976,
36:
1520
7
Schaeffer HJ.
Beauchamp L.
de Miranda P.
Ellion GB.
Bour DJ.
Collins P.
Nature (London)
1978,
272:
583
8
Robins RK.
Srivastava PC.
Narayana VL.
Plowman J.
Paul KD.
J. Med. Chem.
1982,
25:
107
9
Negre J.
Chance ML.
Hanboula SY.
Monsigny M.
Roche AC.
Mayer RM.
Hommel M.
Antimicrob. Agents Chemother.
1992,
2228
10a
Namane A.
Gouyette C.
Fillion MP.
Fillion G.
Huynh DT.
J. Med. Chem.
1992,
35:
3039
10b
Fischer JF.
Harrison AW.
Bundy G.
Wilkinson KF.
Rush BD.
Ruwart MJ.
J.
Med. Chem.
1991,
34:
3140
11
Chu CK.
Wempen I.
Watanabe KA.
Fox JJ.
J. Org. Chem.
1976,
41:
2793 ; and references cited therein
12 Mishra, R. C.; Tewari, N.; Arora,
K.; Tripathi, R. P.; Tiwari, V. K.; Walter R. D.; Srivastava A.
K. Comb. Chem. High Throughput Screening 2002, in press.
13a
Harris L.
Mcdermott G.
Smith K.
Tetrahedron Lett.
1974,
2421
13b
Liotta CL.
Harris HP.
Mc
Bremott Gonzalez T.
Smith K.
Tetrahedron
Lett.
1974,
2417
14
Donnie JS.
Simmons HE.
J. Am. Chem. Soc.
1974,
96:
2252
15
General procedure
for the synthesis of compounds 2a-k, 4a and 4b: β-Amino
ester 1a (1.15 g, 3.12 mmol) and p-n-butyl
phenyl isocyanate (0.546 mL, 3.12 mmol) in anhydrous dichloromethane
(15.0 mL) were magnetically stirred at ambient temperature for 2
h. Solvent was evaporated and the reaction mixture was chromatographed over
a SiO2 column using a gradient of hexane-ethyl
acetate (3:2) as eluent to give compound 2a (1.56
g, 95%). Similarly compounds 2b-k were synthesized in quantitative yield
by reaction with the corresponding isocyanates. For the synthesis
of compounds 4a,b,
2 mmoles of glycosylated β-amino esters 1 were
treated with 1 mmole of diisocyanate under similar experimental
conditions.
16
General procedure
for the synthesis of compounds 3a-k, 5a and 5b:A mixture of compound 2a (0.3 g, 0.622 mmol), 4 Å MS
(0.03 g), TBAB (0.03 g, 0.093 mmol) and DBU (0.093 mL, 0.622 mmol)
in anhydrous toluene (15 mL) was refluxed for 2 h. Solvent was evaporated
and the residue was chromatographed over a SiO2 column
using a gradient of hexane-ethyl acetate (3:1) as eluent
to give compound 3a. Similarly, compounds 3b-k and 5a,b were synthesized
from the corresponding ureidyl derivatives 2b-k and 4a,b, respectively. The yields and reaction
time are given in Table
[1]
.
17
Physical Data
of the precursor of C-nucleosides. 2a:
[α]D = -37.94
(c, 0.437, CHCl3); FAB MS: m/z = 541
(M + H)+;
IR (Neat): cm-1 3346, 2933, 1725, 1667,
1603, 1524, 1080, 1022. 1H NMR (200 MHz, CDCl3): δ 0.90
(t,
J = 7.2 Hz, 3 H,
CH2CH2CH2CH3), 1.25
(t, J = 7.0 Hz, 3 H, -OCH2CH3),
1.32 and 1.51 [s each, 3 H each, >C (CH3)2], 1.55
(m, 4 H, CH2CH2CH2CH3),
2.40 (dd, J = 16.4 Hz and 3.8
Hz, 1 H, H-6a), 2.53 (t, J = 7.7
Hz, 3 H, CH2CH2CH2CH3),
2.80 (dd, J = 16.4 Hz and 8.4
Hz, 1 H,
H-6b), 3.37 (s, 3 H, -OCH3),
3.61 (d, J = 2.4 Hz, 1 H, H-3), 4.11
(q, J = 7.0 Hz, 2 H, -OCH2CH3),
4.51 (m, 3 H, H-4, H-5, -NCHa), 4.60 (d, J = 3.8
Hz, 1 H, H-2), 4.69 (d, J = 16.7 Hz,
1 H, NCHb), 5.89 (d, J = 3.8
Hz, 1 H, H-1), 6.31 (m, 2 H, furyl proton), 7.05 (d, J = 8.4 Hz, 2 H, ArH), 7.24
(d, J = 8.4 Hz, 2 H, ArH), 7.33
(s, 1 H, furyl proton), 7.58 (bs, 1 H, -NHAr). 4a: [α]D = -16.3
(c, 0.33, CHCl3); FAB MS: m/z = 891
(M + H)+; IR (Neat): cm-1 3365,
1729, 1572. 1H NMR (200 MHz, CDCl3): δ 1.22
(t, J = 7.1 Hz, 3 H, -OCH2CH3), 1.45
and 1.26 [s each, 3 H each, >C(CH3)2],
1.54 (s, 1 H,
-NHCH), 2.71 (m, 2 H, H-6), 3.90 (m, 1 H,
H-3), 4.09 (m,
3 H,-OCH2CH3 and H-5),
4.68-4.38 (m, 4 H, -OCH2Ph,
H-2, H-4),
5.95 (d, J = 3.6 Hz, 1 H, H-1),
6.98 (m,1 H, NHAr), 7.17 (m, 7 H, ArH).
18
Physical data
of C-nucleosides. 3a: [α]D = -2.40
(c, 0.250, CHCl3); FAB MS: m/z = 521
(M + Na)+; IR (Neat): cm-1 2932,
1680, 1452, 1376, 1210, 1080, 1017. 1H NMR (300 MHz,
CDCl3): δ 0.92 (t, J = 7.2
Hz, 3 H, CH2CH2CH2CH3), 1.21
and 1.26 [s, 6 H, >C(CH3)2],
1.39 (m, 2 H, CH2CH2-CH2CH3),
1.58 (m, 2 H, CH2CH2CH2CH3),
2.58 (d, J = 9.0 Hz, 1 H, H-5a),
2.62 (t, J = 7.8 Hz, 3 H, CH2CH2CH2CH3), 2.98
(dd, J = 16.8 Hz and 6.6 Hz,
1 H, H-5b), 3.41 (s, 3 H,
-OCH3),
3.72 (d, J = 2.4 Hz, 1 H, H-3′),
4.00 (dd, J = 7.5 Hz and 8.1
Hz, 1 H, H-6), 4.34 (d, J = 15.6
Hz, 1 H, N-CHA), 4.46 (dd, J = 6.9
Hz and 2.7 Hz, 1 H, H-4′); 4.62 (d, J = 3.6 Hz,
1 H, H-2′), 5.28 (d, J = 15.9
Hz, 1 H, -NCHBPh), 5.97 (d, J = 3.6
Hz, 1 H, H-1′), 6.32 (m, 2 H, furyl proton), 7.04 (d,
J = 7.8 Hz, 2 H, ArH), 7.24
(d, J = 7.8 Hz, 2 H, ArH), 7.39 (s,
1 H, furyl proton). 13C NMR: δ 14.41,
22.86, 26.69, 27.37, 30.20, 33.82, 35.05, 35.82, 44.99, 50.84, 58.01, 81.15,
81.49, 84.25, 105.71, 109.40, 110.93, 112.53, 128.77, 129.67, 133.35,
142.97, 143.62, 151.32, 153.14, 168.97. 3b: [α]D = -27.05
(c, 0.425, CHCl3); FAB MS: m/z = 483
(M + H)+; IR (Neat): cm-1 3361,2932,
1652, 1462, 1369, 1201, 1080. 1H NMR (300 MHz,
CDCl3):δ 1.27 [s, 6 H, >C(CH3)2],
2.45 (d, J = 16.6 Hz, 1 H, H-5a),
3.37 (s, 3 H, OCH3), 3.65 (d, J = 3.0
Hz, 1 H, H-3′), 3.98 (two d, J = 6.5 Hz,
1 H, H-6), 4.11 (dd, J = 6.5
Hz and 3.0 Hz, 1 H, H-4′), 4.27 (d, J = 15.7
Hz, 1 H, CHBPh), 4.57 (d, J = 3.7
Hz, 1 H, H-2′), 4.97(d, J = 4.4
Hz, 2 H, -NCH2Ph), 5.14 (d, J = 15.7 Hz,
1 H, CHAPh), 5.92 (d, J = 3.72
Hz, 1 H, H-1′), 6.91 and 7.36 (2 m, 9 H, Ar-H), 8.57 (br
s, 1 H, Ph-OH). 13C NMR:
δ 26.56,
27.11, 30.07, 34.21, 44.35, 49.33, 50.97, 53.80, 57.84, 80.92, 81.10,
84.03, 105.58, 112.52, 118.12, 120.29, 123.12, 127.89, 128.87, 128.98,
130.68, 131.60, 137.64, 155.10, 156.20, 168.16. 3c: [α]D = -9.60
(c, 0.250, CHCl3); FAB MS: m/z = 483
(M + H)+; IR (Neat): cm-1 3371,
2928, 1652, 1461, 1377, 1208, 1080, 1026. 1H
NMR (300 MHz, CDCl3): δ 1.23 and 1.26 [s,
6 H, >C(CH3)2], 2.62 (dd, J = 16.5 Hz and 6.4 Hz, 1 H,
H-5a), 3.03 (d, J = 16.5
Hz, 1 H, H-5b), 3.43 (s, 3 H, OCH3), 3.61
(d, J = 3.0 Hz, 1 H, H-3′),
3.97 (dd, J = 6.3 Hz and 3.01
Hz, 1 H, H-4′), 4.05 (m, 1 H, H-6), 4.55 (d, J = 3.68 Hz, 1 H, H-2′),
4.89 and 4.80 (two d, each J = 14.8
Hz, 1 H each, NCHAPh and NCHBPh), 4.96 and
4.30 (two d, each J = 15.6 Hz,
1 H each, NCHAPhOH and NCHBPhOH), 5.80 (d, J = 3.68 Hz, 1 H, H-1′),
6.89 and 7.27 (two m, 9 H, Ar-H), 8.61 (br s, 1 H, Ph-OH).13C
NMR:
δ 26.71, 27.13, 33.92, 48.09, 50.50, 57.41,
79.80, 80.88, 84.24, 105.14, 112.48, 118.30, 120.39, 122.78, 127.69, 127.74,
128.76, 128.83, 129.04, 130.98, 137.78, 155.72, 156.13, 168.65. 3g: [α]D = -12.0
(c, 0.200, CHCl3); FAB MS: m/z = 453
(M + H)+; IR (Neat): cm-1 3019,
2928, 1685, 1548, 1447, 1413, 1381, 1216. 1H
NMR (200 MHz, CDCl3): δ 1.34 and 1.49 [s
each, 3 H each, >C(CH3)2],
2.64 (m, 2 H, H-5), 3.94 (m, 2 H, H-3′ and H-6), 4.10 (dd, J = 3.0 Hz and 2.7 Hz, 1 H,
H-4′), 4.66 (d, J = 3.0
Hz, 1 H, H-2′), 4.74 (d,
J = 11.7
Hz, 1 H, -OCHAPh), 5.98 (d, J = 3.0
Hz, 1 H, H-1′), 7.04 (d, J = 8.0
Hz, 2 H, Ar-H), 7.24 (m, 2 H, Ar-H), 7.38 (m, 5 H, Ar-H). 13C
NMR: δ 21.20, 26.27, 26.87, 34.21, 46.35, 72.06, 81.39,
81.49, 82.02, 105.14, 112.31, 128.13, 128.38, 128.62, 28.88, 129.53,
129.84, 132.28, 136.34, 138.35, 153.98, 168.46. 3h: [α]D = -26.10
(c,0.475, CHCl3); FAB MS: m/z = 453
(M + H)+; 1H NMR
(200 MHz, CDCl3): δ 1.30 nd 1.43 [s
each, 3 H each, >C(CH3)2],
2.50 (m, 2 H, H-5), 3.82 (m, 1,H, H-6), 3.94 (m, 2 H, H-3′ and
H-4′), 4.42 (d, J = 11.8
Hz, 1 H, -OCHAPh), 4.62 (d, J = 3.3
Hz, 1 H, H-2′), 4.68 (d, J = 11.8
Hz, 1 H, -OCHBPh), 4.92 (br s, 2 H, NCH2),
5.88 (br s, NH and H-1′), 7.29(m, 10 H, ArH). 13C NMR: δ 26.16,
26.74, 29.62, 31.38, 31.85, 33.59, 43.35, 45.98, 71.89, 81.14, 81.86,
104.95, 112.16, 127.23, 128.04, 128.28, 128.50, 128.77, 136.26,
137.50, 153.79, 168.09. 5a: [α]D = -24.20
(c, 0.14, CH3OH); FAB MS: m/z = 805
(M + Li)+; 1H NMR
(200 MHz, CDCl3): δ 1.46 and 1.28 [s
each,
3 H each, >C(CH3)2],
2.50 (m, 2 H, H-5), 3.66 (m, 1 H,
H-6), 3.90 (d, J = 3.0 Hz, 1 H, H-3′),
4.42 (d, J = 11.8 Hz,
1
H, -OCHAPh), 4.67 (d, J = 3.3
Hz, 1 H, H-2′), 4.68 (d, J = 11.8
Hz, 1 H, -OCHBPh), 5.95 (d, J = 3.6
Hz, 1 H, H-1′), 6.98 (s,1 H, NHCO), 7.30 (m, 7 H, ArH). 13C
NMR: 137, 134, 128,121, 112, 105, 80, 81,82,72, 53, 52, 26, 25. 5b:
[α]D = -23.20
(c, 0.13, CH3OH); FAB MS: m/z = 799
(M + H)+;
IR (Neat): cm-1 3361 (NH), 1614 (CO). 1H
NMR (200 MHz, CDCl3): δ 1.46 and 1.28 [s
each, 3 H each, >C(CH3)2],
2.62 and 2.97 (m each, 2 H each, H-5), 3.39 and 3.60 (m, each 1
H, diastereomeric H-6), 4.26 (m, 2 H, dia-stereomeric H-3′ and
H-4′), 4.55 (m, 3 H, H-2′, -OCHAPh and
-OCHBPh), 5.95 and 5.90 (d, J = 4.2
Hz, 1 H, diastereo-meric H-1′), 7.29 (m, 7 H, ArH). 13C
NMR: 176, 172, 167,140, 137, 128, 124, 114, 112, 111, 105, 82.6,
82.07, 81.8, 72.29, 52.6, 50.06, 46, 26, 25.
